CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane

被引：0
|
作者：
O'Shaughnessy, Joyce [1 ]
Piccart, Martine [2 ]
Schwartzberg, Lee [3 ]
Cortes, Javier [4 ,5 ,6 ,7 ]
Harbeck, Nadia [8 ]
Im, Seock-Ah [9 ]
Rugo, Hope [10 ]
Untch, Michael [11 ]
Yardley, Denise [12 ,13 ]
Bondarenko, Igor [14 ]
Dieras, Veronique [15 ]
Pegram, Mark [16 ]
Kroll, Stew [17 ]
O'Connell, Joseph [17 ]
Vacirca, Jeff [17 ]
Wei, Thomas [17 ]
Tang, Kevin [17 ]
Seidman, Andrew [18 ]
机构：
[1] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA
[2] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[3] West Canc Ctr, Memphis, TN USA
[4] IOB Inst Oncol, Quironsalud Grp, Madrid, Spain
[5] Vall dHebron Inst Oncol, Madrid, Spain
[6] IOB Inst Oncol, Quironsalud Grp, Barcelona, Spain
[7] Vall dHebron Inst Oncol, Barcelona, Spain
[8] Univ Munchen LMU, Brustzentrum, Munich, Germany
[9] Seoul Natl Univ Hosp, Seoul, South Korea
[10] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[11] Helios Hosp Berlin Buch, Berlin, Germany
[12] Sarah Cannon Res Inst, Nashville, TN USA
[13] Tennessee Oncol, Nashville, TN USA
[14] Dnipropetrovsk Med Acad, Dnipro, Ukraine
[15] Ctr Eugene Marquis, Rennes, France
[16] Stanford Womens Canc Ctr, Palo Alto, CA USA
[17] Odonate Therapeut Inc, San Diego, CA USA
[18] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-OT1-08-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-08-09
引用
收藏
页数：3
相关论文
共 50 条
  • [31] SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+metastatic breast cancer (MBC).
    Rugo, Hope S.
    Pegram, Mark D.
    Gradishar, William John
    Cortes, Javier
    Curigliano, Giuseppe
    Wigginton, Jon M.
    Lechleider, Robert Joseph
    Cardoso, Fatima
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] The PROCEED trial KCSG BR11-01: Phase III multicenter randomized open label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer
    Park, I. H.
    Lee, K. S.
    Im, S-A
    Jung, K. H.
    Park, K. H.
    Im, Y-H
    Lee, S.
    Kim, Y. J.
    Kim, H-J
    Lee, S.
    Lee, M. H.
    Kim, T-Y
    Lee, K-H
    Kim, S-B
    Ahn, J-H
    Nam, B-H
    Ro, J.
    CANCER RESEARCH, 2013, 73
  • [33] Cost-effectiveness of lapatinib plus capecitabine in women with HER2+metastatic breast cancer who have received prior therapy with trastuzumab
    Delea, Thomas E.
    Tappenden, Paul
    Sofrygin, Oleg
    Browning, Dominy
    Amonkar, Mayur M.
    Karnon, Jon
    Walker, Mel D.
    Cameron, David
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2012, 13 (05): : 589 - 603
  • [34] Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)
    Signorovitch, James
    Wang, Jenny
    Tan, Ruo-Ding
    Thomason, Darren
    Kageleiry, Andrew
    Swallow, Elyse
    CANCER RESEARCH, 2015, 75
  • [35] Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
    Thomas E. Delea
    Paul Tappenden
    Oleg Sofrygin
    Dominy Browning
    Mayur M. Amonkar
    Jon Karnon
    Mel D. Walker
    David Cameron
    The European Journal of Health Economics, 2012, 13 : 589 - 603
  • [36] Saci-IO HR plus : Randomized phase II trial of sacituzumab govitecan (SG) plus /- pembrolizumab in PD-L1+hormone receptor-positive (HR+) / HER2-metastatic breast cancer (MBC).
    Garrido-Castro, Ana Christina
    Keenan, Tanya Elizabeth
    Li, Tianyu
    Lange, Paulina
    Callahan, Catherine
    Guerriero, Jennifer
    Tayob, Nabihah
    Anderson, Leilani
    Stover, Daniel G.
    Gogineni, Keerthi
    Carey, Lisa A.
    Nanda, Rita
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Neratinib plus capecitabine (N plus C) vs lapatinib plus capecitabine (L plus C) in Asians with HER2+metastatic breast cancer (MBC) previously treated with two or more HER2-directed regimens: A Pan-Asian analysis of the phase III NALA trial
    Dai, M. S.
    Feng, Y. H.
    Chen, S. W.
    Masuda, N.
    Sangai, T.
    Yau, T.
    Kwong, A.
    Ngan, R.
    Yap, Y. S.
    Ang, P. C. S.
    Ow, S.
    Lee, K. S.
    Kim, S. B.
    Chung, H. C.
    Keyvanjah, K.
    Bebchuk, J.
    Chen, M-C. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1259 - S1259
  • [38] Proxalutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase Ic Study
    Li, Hui-Ping
    Song, Guohong
    Jiang, Hanfang
    Liang, Xu
    Wang, Xiaojia
    Yang, Hua
    Zhang, Lili
    Tong, Youzhi
    CANCER RESEARCH, 2024, 84 (09)
  • [39] Patterns of care and patient characteristics in postmenopausal women with HER2+and hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Sharma, P. P.
    Sail, K.
    Delea, T. E.
    Forsyth, M. T.
    Halm, M.
    Nagarwala, Y. M.
    Lopez, W.
    Patt, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer
    Xu, Binghe
    Zhang, Pin
    Sun, Tao
    Zhang, Qingyuan
    Jiang, Zefei
    Yuan, Zhongyu
    Wang, Xiaojia
    Cui, Shude
    Teng, Yuee
    Hu, Xi-Chun
    Yang, Junlan
    Pan, Hongming
    Tong, Zhongsheng
    Li, Huiping
    Yao, Qiang
    Wang, Yongsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345